Ironwood Pharmaceuticals (IRWD) Return on Capital Employed (2011 - 2026)
Ironwood Pharmaceuticals (IRWD) posted Return on Capital Employed of 111.57% for Q1 2026, up 74.73% sequentially from 63.85% in Q4 2025, and up 9335.0% YoY from 1.18% in Q1 2025.
Ironwood Pharmaceuticals (IRWD) Return on Capital Employed (2011 - 2026) Analysis & Trends
Ironwood Pharmaceuticals has reported Return on Capital Employed for 16 years, with the latest figure at 111.57% in Q1 2026.
- Quarterly Return on Capital Employed rose 9335.0% year-over-year to 111.57% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 111.57% (up 9335.0% YoY) and the FY2025 annual result came in at 74.8%, up 4978.0% from the prior year.
- Return on Capital Employed advanced to 111.57% in Q1 2026 per IRWD's latest filing, from 63.85% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 111.57% in Q1 2026 and troughed at 491.1% in Q1 2024.
- A 5-year average of 48.57% and a median of 24.32% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed plunged 51398 bps in 2024, then surged 50932 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 23.96% in 2022, then tumbled by 1882 bps to 426.89% in 2023, then surged by 107 bps to 28.1% in 2024, then surged by 127 bps to 63.85% in 2025, then surged by 75 bps to 111.57% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 111.57%, 63.85%, and 97.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Ironwood Pharmaceuticals | 669.13 Mn | 590.00 Mn | - | 71.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.61% |
| Mar 31, 2026 | 111.57% |
| Dec 31, 2025 | 63.85% |
| Sep 30, 2025 | 97.00% |
| Jun 30, 2025 | 71.51% |
| Mar 31, 2025 | 18.21% |
| Dec 31, 2024 | 28.10% |
| Sep 30, 2024 | 28.91% |
| Jun 30, 2024 | 30.56% |
| Mar 31, 2024 | -491.10% |
| Dec 31, 2023 | -426.89% |
| Sep 30, 2023 | -323.13% |
| Jun 30, 2023 | -154.43% |
| Mar 31, 2023 | 22.88% |
| Dec 31, 2022 | 23.96% |
| Sep 30, 2022 | 24.32% |
| Jun 30, 2022 | 23.38% |
| Mar 31, 2022 | 25.55% |
| Dec 31, 2021 | 24.67% |
| Sep 30, 2021 | 25.30% |